Natera's Signatera Test Outperforms AMERK in Merkel Cell Carcinoma Recurrence Prediction — Natera, Inc.

Event summary

Natera's Signatera test demonstrated superior predictive power over AMERK in detecting Merkel cell carcinoma (MCC) recurrence, with a hazard ratio difference of 6.6 (p < 0.001).
Signatera achieved a sensitivity of 90% compared to AMERK's 55%, and detected recurrence earlier by a median lead time of 5.1 months vs. 2.1 months.
The study, published in JAMA Dermatology on July 22, 2026, involved 169 patients across multiple centers.
Signatera's accuracy remains consistent regardless of viral status or immunotherapy exposure, addressing key limitations of AMERK.

The big picture

This study reinforces the shift toward molecular diagnostics in cancer surveillance, particularly for rare but aggressive diseases like MCC. Natera's ability to offer a universally reliable biomarker could reshape how clinicians monitor recurrence across diverse patient populations. The findings also highlight the growing importance of cell-free DNA testing in precision oncology.

What we're watching

Adoption Dynamics: How quickly Natera can integrate Signatera into standard clinical practice for MCC surveillance, given its broader applicability.
Competitive Positioning: Whether this validation will solidify Signatera's role in the NCCN Guidelines and expand its market share against other diagnostic tools.
Regulatory Impact: The pace at which regulatory bodies may endorse Signatera for broader oncology applications beyond MCC.